Rare co-existence of disease or pathology Background:
Background
In daily clinical situations, physicians often encounter pathologies of unknown etiology that are initially unpredictable, and there is a tendency to consider these conditions in an integrated and complicated fashion. Amyloid light-chain (AL) amyloidosis is a rare disease with an estimated prevalence of 5-12 cases per million population per year [1, 2] . Hyper-immunoglobulin E (IgE) syndrome is a rare immunodeficiency disease characterized by refractory skin abscesses, lung infections, skeletal abnormalities, and hyper-IgE-emia [3] . Moreover, hyper-IgE syndrome commonly occurs in an autosomal dominant inheritance pattern. Indeed, our patient had experienced chronic inflammatory and recurrent refractory skin abscesses, although he had no family history of hyper-IgE syndrome and none of the characteristic skeletal abnormalities. It was difficult to interpret this systemic amyloidosis as a consequence of hyper-IgE syndrome. Therefore, we concluded that the systemic amyloidosis and hyper-IgE-emia of this patient were independent. Here, we report a rare case of early-stage heart failure with preserved ejection fraction (HFpEF) of the left ventricle that was finally diagnosed as primary AL amyloidosis based on tissue biopsy results.
Case Report
A 53-year-old man came to our hospital with signs and symptoms of acute heart failure after a 2-week history of progressive breathlessness. He had a history of recurrent skin abscesses and atopic dermatitis and regularly visited a dermatologist in our hospital. On arriving at our hospital, his extremities were warm and dry. According to the New York Heart Association criteria, he had class III congestive heart failure (CHF). An electrocardiogram revealed diffuse nonspecific T-wave changes, low voltage (<5 mm) in the extremity leads and poor R-wave progression in the anterior chest leads. Multiple sporadic ventricular premature beats were seen (Figure 1) . Chest x-ray film confirmed right pleural effusion, and mild cardiomegaly but no pulmonary congestion (Figure 2 ). Blood tests showed severely elevated B-type natriuretic peptide (901 pg/mL) and markedly raised IgE (12 000 IU/mL) without eosinophilia (eosinophil count of 1.62×10 echocardiography ( Figure 3 ) showed concentric mild left ventricular (LV) hypertrophy (12 mm) without the characteristic granular sparkling appearance and pericardial effusion, preserved ejection fraction (60%), and bi-atrial enlargement with normal ventricular chambers. Doppler-derived LV diastolic filling demonstrated a restrictive pattern with a trans-mitral early filling wave deceleration time of 160 ms and an elevated E/A ratio of 2.8. A markedly elevation of E/e' ratio of 27.3 indicated elevated LV filling pressure. On day 1 of hospitalization, we prescribed an angiotensin-converting enzyme (ACE) inhibitor and low-dose diuretics.
On day 3 of hospitalization, after initiating ACE inhibitor and diuretic therapy, the patient's symptoms resolved. The dermatologists performed a biopsy of a blue macula of the forehead skin. On day 4, we introduced a low-dose b-blocker and performed an endomyocardial biopsy (EMB), obtaining 3 fragments of the right ventricular septum because diagnostic confirmation of cardiac amyloidosis requires the demonstration of amyloid deposits. In addition, we performed right heart catheterization (RHC), and coronary angiography to exclude obstructive coronary artery disease. The data obtained from the RHC indicated subset type IV according to the Forrester classification. The right ventricular pressure curve did not show a dip-and-plateau configuration.
Skin biopsy revealed hyperkeratosis in the epidermis and mild inflammatory changes throughout the dermis with an infiltration of lymphocytes. The specimen exhibited apple-green birefringence with polarized light after Congo red staining ( Figure 4 ). Histological examination of the myocardial specimen showed no signs suggesting myocarditis, eosinophilic granulomas, or cardiomyopathy with iron deposition, but Congo red staining revealed amyloid deposits ( Figure 5 ). In addition, a strongly positive immunohistochemical reaction to immunoglobulin l-chain in the myocardial interstitium led us to diagnose this patient's systemic amyloidosis as AL amyloidosis. The patient generally tolerated the low-dose b-blocker well and was discharged on day 10 with no complications. The patient is currently being followed-up at 6-month intervals as an outpatient, with no exacerbation of the CHF thus far.
Discussion
Amyloidosis develops as a result of deposition of insoluble amyloid fibrils in the extracellular spaces of organs and tissues and clinically varies from mild to severe. Amyloidosis can be divided broadly into primary, hereditary, systemic senile, isolated atrial, reactional or secondary, and dialysis-related types. Initially, we considered this patient's condition as a disease associated with hyper-IgE syndrome [3] . His IgE level was markedly elevated, and he had experienced recurrent refractory skin abscesses. We considered a scenario whereby the increasing SAA produced by chronic inflammatory disease had developed into AA amyloidosis, also known as secondary amyloidosis. This scenario meant that the hyper-IgE syndrome had progressed to the point where amyloid protein was systemically deposited in the patient's organs. However, the patient's SAA was normal and AA amyloidosis involving the heart is unusual owing to the amyloid's tissue-specific affinity [4] [5] [6] . In addition, he had no family history of hyper-IgE syndrome or characteristic skeletal abnormalities. Upon excluding AA amyloidosis, 2 subtypes of amyloidosis seemed more probable: AL amyloidosis and systemic senile type, which occurs by deposition of wild-type transthyretin amyloid. Ng et al. [7] reported important differences in the prognosis and evolution of these 2 subtypes, with a mean survival after cardiovascular involvement of 11 and 75 months, respectively. Additionally, the insidious course of the disease is the rule for senile amyloidosis, whereas the AL type shows rapid evolution of symptoms and a higher cardiac involvement. We finally diagnosed primary AL amyloidosis by performing special immunological staining of tissues obtained from the EMB and skin biopsy. In the absence of confirmed plasma cell dyscrasia, immunohistochemical techniques are the most useful for classifying the type of amyloidosis [8] . Several studies concluded that cardiac involvement in amyloidosis is the major determinant of mortality in patients with AL amyloidosis, and the prognosis is very poor [9] [10] [11] . However, Quevedo et al. [12] insisted that early diagnosis and prompt therapy are crucial to the reversal of AL-related cardiac dysfunction. In support of this idea, we prescribed an ACE inhibitor and b-blocker as conventional therapies for CHF; accordingly, the patient's CHF condition did not worsen. Amyloid deposition essentially restructures the heart and restricts it from stretching and properly filling with blood, resulting in the so-called restrictive cardiomyopathy (RCM). In time, RCM progresses from diastolic to systolic dysfunction and eventually to heart failure [13] . A report demonstrated the importance of the Doppler-derived restrictive filling pattern in the prognosis of hypertrophic cardiomyopathy [14] . Our patient's cardiomyopathy may have been in a very early stage because his systolic function was within the normal range and therefore was termed HFpEF. In the early stages of RCM, systolic function may be normal, although deterioration of systolic function is usually observed as the disease progresses [15] . The prognosis of HFpEF is difficult to determine because the definition of HFpEF is ambiguous, and a cut-off for systolic function has not been determined (indeed, there are 2 groups: EF ³50% and EF >45%). Furthermore, most studies did not include diastolic function in their inclusion criteria [16] [17] [18] [19] [20] . The prevalence of HFpEF has been increasing along with the aging population [16, 17] . In contrast to HF with reduced EF, there has been little or no progress in developing strategies for treating HFpEF over the last 20 years [18] [19] [20] . However, diagnosing and treating comorbidities for patients with HFpEF is very important. HFpEF has been associated with the presence of hypertension, diabetes mellitus, obesity, coronary artery disease, and LV hypertrophy, which are also common in elderly people but had not previously been linked so strongly with cardiac amyloidosis. A few studies have reported an approximately 10% frequency of cardiac amyloidosis in patients with HFpEF [21, 22] .
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Conclusions
Although the heart is a common organ for amyloid deposition, cardiac amyloidosis may be an under-appreciated cause of hypertrophic cardiomyopathy. We anticipate new specific tools for diagnosing infiltrative cardiomyopathy in the early stage of HFpEF and suggest aggressive intervention to prevent the progression of the CHF.
